Document:

Exhibit 10.36

 

RECEPTOS, INC.

RESTRICTED STOCK ISSUANCE AGREEMENT

(Marcus Boehm)

 

THIS RESTRICTED STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of July 30, 2009 by and between Receptos, Inc., a Delaware corporation (the “Company”), and Marcus Boehm, an individual (the “Stockholder”).

 

THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.                                      Issuance of Shares.

 

1.1                               Issuance.  The Company hereby issues to Stockholder, and Stockholder hereby accepts, Eight Hundred Thousand (800,000) shares (the “Shares”) of the Company’s Common Stock, par value $0.001 (the “Common Stock”).  The parties acknowledge and agree that, for purposes of this Agreement, the Shares are assumed to have a fair market value, as of the date of this Agreement, of $0.01 per Share.

 

1.2                               Assignment.  Concurrently with the execution of this Agreement, the Stockholder shall deliver to the Secretary of the Company a duly executed blank Assignment Separate from Certificate (in the form attached hereto as Exhibit A) and any additional documents required by the Company as a condition for the issuance of the Shares.

 

1.3                               Delivery of Certificates.  The certificates representing the Shares issued hereunder and subject to the Company’s Repurchase Right (as defined in Article 5 below) shall be held in escrow by the Secretary of the Company (as provided in Article 6 below).

 

2.                                      Securities Law Compliance.

 

2.1                               Exemption From Registration.  The Shares have not been registered under the Securities Act of 1933, as amended (the “1933 Act”), and are being issued to the Stockholder in reliance upon the exemption from such registration provided by Section 4(2) of the 1933 Act based on the representations and warranties made by the Stockholder herein.

 

2.2                               Restricted Securities.

 

(a)                                 The Stockholder hereby confirms that the Stockholder has been informed that the Shares are “restricted securities” under the 1933 Act and may not be resold or transferred unless the Shares are first registered under the federal securities laws or unless an exemption from such registration is available.  Accordingly, the Stockholder hereby acknowledges that the Stockholder is prepared to hold the Shares for an indefinite period of time.

 

(b)                                 The Stockholder is aware of the adoption of Rule 144 by the Commission, promulgated under the 1933 Act (“Rule 144”), which permits limited public resales of securities acquired in a nonpublic offering, subject to the satisfaction of certain conditions, including, among other things, the following:  (i) the availability of certain current public information about the issuer; (ii) the sale being through a broker in an unsolicited “broker’s transaction”; and (iii) the amount of securities being sold during any three (3) month period not

 

 

exceeding specified limitations.  The Stockholder is aware that Rule 144 is not presently available to exempt the sale of the Shares from the registration requirements of the 1933 Act.  The Stockholder further represents that the Stockholder understands that at the time the Stockholder wishes to sell the Shares there may be no public market upon which to make such a sale, and that, even if such a public market exists for the Common Stock, the Company may not satisfy the current public information requirement of Rule 144 or other conditions under Rule 144 which are required of the Company.  As a result of the foregoing, the Stockholder understands that the Stockholder may be precluded from selling the Shares under Rule 144.

 

(c)                                  The Stockholder represents that (i) prior to acquisition of the Shares, the Stockholder acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Shares; (ii) the Stockholder has such knowledge and experience in financial and business matters as to make the Stockholder capable of evaluating the risks of the prospective investment and to make an informed investment decision; and (iii) the Stockholder is able to bear the economic risk of the Stockholder’s investment in the Shares.  The Stockholder agrees not to make, without the prior written consent of the Company, any public offering or sale of the Shares although permitted to do so pursuant to Rule 144(k) promulgated under the 1933 Act, until the earlier of the date on which the Company effects its initial registered public offering pursuant to the 1933 Act or the date on which it becomes a registered company pursuant to section 12(g) of the Securities and Exchange Act of 1934, as amended.

 

2.3                               Disposition of Shares.  The Stockholder hereby agrees that the Stockholder shall not make any disposition of the Shares (other than a permitted transfer under Section 4.1 below) unless and until:

 

(a)                                 the Stockholder shall have notified the Company of the proposed disposition and provided a written summary of the terms and conditions of the proposed disposition;

 

(b)                                 the Stockholder shall have complied with all requirements of this Agreement applicable to the disposition of the Shares; and

 

(c)                                  the Stockholder, if requested by the Company, shall have provided the Company with an opinion of counsel in form and substance satisfactory to the Company, that (i) the proposed disposition does not require registration of the Shares under the 1933 Act or (ii) all appropriate action necessary for compliance with the registration requirements of the 1933 Act or the requirements of any exemption from registration available under the 1933 Act (including Rule 144) have been taken.

 

The Company shall not be required (x) to transfer on its books any Shares that have been sold or transferred in violation of the provisions of this Article 2 nor (y) to treat as the owner of the Shares, or otherwise to accord voting or dividend rights to, any transferee to whom the Shares have been transferred in contravention of this Agreement.

 

2.4                               Restrictive Legends.  In order to reflect the restrictions on the disposition of the Shares, the stock certificates for the Shares will be endorsed with restrictive legends, including the following legends as applicable:

 

2

 

(a)                                 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE, AND MAY BE OFFERED AND SOLD ONLY IF REGISTERED AND QUALIFIED PURSUANT TO FEDERAL AND STATE SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION AND QUALIFICATION UNDER FEDERAL AND STATE SECURITIES LAWS IS NOT REQUIRED.”

 

(b)                                 The legends set forth in Articles 5 and 7 below.

 

(c)                                  Any legend(s) required by the authorities of any state in connection with the issuance of the Shares.

 

3.                                      Special Provisions.

 

3.1                               Stockholder Rights.  Until such time as the Company actually exercises its repurchase rights under this Agreement, the Stockholder (or any successor in interest) shall have all the rights of a stockholder (including voting and dividend rights) with respect to the Shares, including the Shares held in escrow under Article 6 below, subject, however, to the transfer restrictions of Articles 4 and 7 below.

 

3.2                               Section 83(b) Election.  The Stockholder understands that under Section 83 of the Internal Revenue Code of 1986, as amended (the “Code”), the difference between the purchase price paid for the Shares, if any, and the fair market value of such Shares on the date any forfeiture restrictions applicable to such Shares lapse will be reportable as ordinary income at that time.  For this purpose, the term “forfeiture restrictions” includes the right of the Company to repurchase the Shares under Article 5 below.  The Stockholder understands that the Stockholder may elect to be taxed at the time the Shares are acquired hereunder (which would result in a tax on the amount by which the fair market value of the Shares is in excess of the purchase price, if any), rather than when such Shares cease to be subject to such forfeiture restrictions, by filing an election under Section 83(b) of the Code with the U.S. Internal Revenue Service within thirty (30) days after the date of issuance hereunder.  The form for making this election is attached hereto as Exhibit B.  The Stockholder understands that failure to make this filing within such thirty (30) day period will result in the recognition of ordinary income by Stockholder as the forfeiture restrictions lapse (notwithstanding, for example and without limitation, the absence of any ability by the Stockholder to sell the Shares at such time).

 

3.3                               Market Stand-Off.

 

(a)                                 In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the 1933 Act (including, without limitation, the Company’s initial public offering), the Stockholder shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or agree to engage in any of the foregoing transactions with respect to any Shares without the prior written consent of the Company or its underwriters, for such period of time after the effective date of such registration statement as may be requested by the Company or such underwriters (not to exceed one hundred eighty (180) days).

 

3

 

(b)                                 The Stockholder shall be subject to the market stand-off provisions of this Section 3.3 with respect to underwritten public offerings of the Company’s equity securities following the initial such offering only if the officers and directors of the Company are also subject to similar arrangements.

 

(c)                                  In the event of any stock dividend, stock split, recapitalization, or other change affecting the Common Stock effected without receipt of consideration, then any new, substituted, or additional securities distributed with respect to the Shares shall be immediately subject to the provisions of this Section 3.3, to the same extent the Shares are at such time covered by such provisions.

 

3.4                               Stop Transfer.  In order to enforce the provisions of Section 3.3 above, the Company may impose stop-transfer instructions with respect to the Shares until the end of the applicable stand-off period.

 

4.                                      Transfer Restrictions.

 

4.1                               Restriction on Transfer.  The Stockholder shall not transfer, assign, encumber or otherwise dispose of any of the Shares that are subject to the Company’s Repurchase Right under Article 5 below; provided, however, that such restriction on transfer shall not be applicable if the Stockholder receives prior written consent from the Company to (i) a gratuitous transfer of the Shares made to the Stockholder’s ancestors, descendents (including adopted children) or spouse or to trusts, partnerships or other entities for the benefit of such persons or the Stockholder (“Exempt Transfers”); (ii) a transfer of title to the Shares effected pursuant to the Stockholder’s will or the laws of intestate succession; or (iii) a transfer to the Company in pledge as security for any purchase-money indebtedness incurred by the Stockholder in connection with the acquisition of the Shares.

 

4.2                               Transferee Obligations.  Each person (other than the Company) to whom the Shares are transferred (including, as applicable, by means of one of the permitted transfers specified in Section 4.1 above) must, as a condition precedent to such transfer, acknowledge in writing to the Company that such person is bound by the provisions of this Agreement and that the transferred Shares are subject to (i) the Company’s Repurchase Right granted hereunder (as applicable - i.e., to the extent that the transferred Shares are not vested free of such Repurchase Right), (ii) the Company’s Right of First Refusal (as defined below), and (iii) the market stand-off provisions of Section 3.3 above, to the same extent such Shares would be so subject if retained by the Stockholder.

 

4.3                               Definition of Owner.  For purposes of Articles 5, 6 and 7 below, the term “Owner” shall include the Stockholder and all subsequent holders of the Shares who derive their chain of ownership through a permitted transfer from the Stockholder (including, as applicable, in accordance with Section 4.1 above).

 

4

 

5.                                      Repurchase Right.

 

5.1                               Grant.  The Company is hereby granted the right (the “Repurchase Right”), exercisable at any time during the ninety (90) day period following the date the Stockholder ceases (the “Cessation Date”) for any reason to be a Service Provider (as defined below) to the Company, to repurchase at $0.01 per Share (the “Repurchase Price”) all or (at the discretion of the Company) any portion of the Shares in which the Stockholder has not acquired a vested interest in accordance with Section 5.3 or Section 5.6 below as of the Cessation Date (the “Unvested Shares”).  For purposes of this Agreement, the Stockholder shall be deemed to be a “Service Provider” to the Company for so long as the Stockholder is rendering services to the Company or one or more of its parent or subsidiary corporations as an employee, director or consultant.

 

5.2                               Exercise of the Repurchase Right.  The Repurchase Right shall be exercisable by written notice delivered to the Owner of the Unvested Shares prior to the expiration of the ninety (90) day period specified in Section 5.1 above.  The notice shall indicate the number of Unvested Shares to be repurchased and the date on which the repurchase is to be effected, such date to be not more than thirty (30) days after the date of notice.  To the extent one or more certificates representing the Unvested Shares may have been previously delivered out of escrow to the Owner, then the Owner shall, prior to the close of business on the date specified for the repurchase, deliver to the Secretary of the Company the certificates representing the Unvested Shares to be repurchased, properly endorsed for transfer.  The Company shall, concurrently with the receipt of such stock certificates, pay to the Owner in cash or cash equivalents (including the cancellation of any purchase-money indebtedness), an amount equal to the Repurchase Price for the Unvested Shares that are to be repurchased.

 

5.3                               Termination of the Repurchase Right.

 

(a)                                 Lapse of Right.  The Repurchase Right shall terminate with respect to any Unvested Shares for which it is not timely exercised under Section 5.2 above.  In addition, the Repurchase Right shall terminate with respect to any and all Shares in which the Stockholder vests (i) in accordance with the schedules set forth in Section 5.3(b) and Section 5.3(c) below or (ii) pursuant to any applicable vesting acceleration event as provided in Section 5.6 below.  Accordingly, provided the Stockholder continues to be a Service Provider to the Company, the Stockholder shall acquire a vested interest in, and the Repurchase Right shall lapse with respect to, the Shares in accordance with the vesting schedules set forth in Section 5.3(b) and Section 5.3(c) below (and, as applicable, the accelerated vesting provisions of Section 5.6 below).

 

(b)                                 Time-Based Shares.  Measured from the effective time of the combination (through a subsidiary merger) of the Company (formerly known as Receptor Pharmaceuticals, Inc.) and Apoptos, Inc. (the “Vesting Measurement Date”), the Stockholder shall acquire a vested interest in sixty-two and one-half percent (62.5%) of the Shares (i.e., Five Hundred Thousand (500,000) shares of Common Stock — the “Time-Based Shares”), and the Repurchase Right shall lapse as to such Time-Based Shares, as follows (so long as the Stockholder continues to be a Service Provider to the Company):

 

5

 

(1)                                 twenty-five percent (25%) of the total Time-Based Shares (i.e., One Hundred Twenty-Five Thousand (125,000) shares of Common Stock) shall vest on the first (1st) anniversary of the Vesting Measurement Date; and

 

(2)                                 1/48th of the total Time-Based Shares shall vest on the same day of each successive month after the first (1st) anniversary of the Vesting Measurement Date such that one hundred percent (100%) of the Time-Based Shares will have become vested (assuming the Stockholder continues to be a Service Provider) as of the fourth (4th) anniversary of the Vesting Measurement Date.

 

(c)                                  Milestone-Based Shares.  The Stockholder shall acquire a vested interest in thirty-seven and one-half percent (37.5%) of the Shares (i.e., Three Hundred Thousand (300,000) shares of Common Stock — the “Milestone-Based Shares”), and the Repurchase Right shall lapse as to such Milestone-Based Shares, as follows so long as the Stockholder continues to be a Service Provider to the Company:

 

(1)                                 fifty percent (50%) of the total Milestone-Based Shares (i.e., One Hundred Fifty Thousand (150,000) shares of Common Stock — the “First Milestone Shares”) shall vest as follows:

 

(A)                               twenty-five percent (25%) of the total First Milestone Shares (i.e., Thirty-Seven Thousand Five Hundred (37,500) shares of Common Stock) upon the dosing of the first patient in the first Phase I clinical study of an S1P1 agonist (the “First Candidate”) under an Investigational New Drug application (or any foreign equivalent application) allowed by the United States Food and Drug Administration (or any foreign equivalent administrative body unless determined by the Company’s Board of Directors not to be acceptable for this purpose) (in any applicable case, an “IND”) where such S1P1 agonist is covered by any intellectual property right held (whether owned, licensed or otherwise controlled) by the Company (the “First Milestone”); and

 

(B)                               an amount equal to 1/48th of the total First Milestone Shares shall vest on the same day of each successive month following the occurrence of the First Milestone such that 100% of the First Milestone Shares will have become vested (assuming the Stockholder continues to be a Service Provider) as of the third (3rd) anniversary of the occurrence of the First Milestone; and

 

(2)                                 fifty percent (50%) of the total Milestone-Based Shares (i.e., One Hundred Fifty Thousand (150,000) shares of Common Stock — the “Second Milestone Shares”) shall vest as follows:

 

(A)                               twenty-five percent (25%) of the total Second Milestone Shares (i.e., Thirty-Seven Thousand Five Hundred (37,500) shares of Common Stock) upon the dosing of the first patient in the first Phase I clinical study of a novel GPCR agonist or antagonist (other than the First Candidate, if applicable) under an IND where such novel GPCR agonist or antagonist is covered by any intellectual property right held (whether owned, licensed or otherwise controlled) by the Company (the “Second Milestone”); and

 

6

 

(B)                               an amount equal to 1/48th of the total Second Milestone Shares shall vest on the same day of each successive month following the occurrence of the Second Milestone such that 100% of the Second Milestone Shares will have become vested (assuming the Stockholder continues to be a Service Provider) as of the third (3rd) anniversary of the occurrence of the Second Milestone;

 

provided, however, that, so long as the Stockholder continues to be a Service Provider to the Company, any Milestone-Based Shares that have not previously vested shall vest upon the tenth (10th) anniversary of the Vesting Measurement Date.

 

Note:  in the event of any substantial change in the Company’s strategy that renders highly improbable or impossible the achievement of the First Milestone or the Second Milestone, the Company will, in the discretion of the Company’s Board of Directors, offer the Stockholder a modified definition for the First Milestone and/or Second Milestone, as applicable, to reflect the Company’s changed strategy (which, if agreeable to the Stockholder, will be incorporated into an amendment to this Agreement).

 

(d)                                 Other Provisions.  Notwithstanding the foregoing provisions of Sections 5.3(b) or 5.3(c) (or Section 5.6 below), all Shares as to which the Repurchase Right lapses shall continue to be subject to (i) the market stand-off provisions of Section  3.3 above and (ii) the Company’s Right of First Refusal.

 

5.4                               Fractional Shares.  No fractional shares shall be repurchased by the Company.  Accordingly, should the Repurchase Right extend to a fractional share at the time the Stockholder ceases to be a Service Provider, then such fractional share shall be added to any fractional share in which the Stockholder is at such time vested in order to make one whole vested share no longer subject to the Repurchase Right.

 

5.5                               Additional Shares or Substituted Securities.  In the event of any stock dividend, stock split, recapitalization or other change affecting the Common Stock effected without receipt of consideration, then any new, substituted or additional securities or other property (including money paid other than as a regular cash dividend) which is by reason of any such transaction distributed with respect to the Shares shall be immediately subject to the Repurchase Right, but only to the extent the Shares are at the time covered by the Repurchase Right.  Appropriate adjustments to reflect the distribution of such securities or property shall be made to the number of Shares hereunder and to the price per share to be paid upon the exercise of the Repurchase Right in order to reflect the effect of any such transaction upon the Company’s capital structure; provided, however, that the aggregate Repurchase Price shall remain the same.

 

7

 

5.6                               Vesting Acceleration.

 

(a)                                 Acceleration Events.

 

(1)                                 Termination Without Cause or Constructive Termination prior to any Corporate Transaction.  In the event of any Termination without Cause or any Constructive Termination prior to any Corporate Transaction, the following shall occur:  (i) if the First Milestone shall have occurred prior to such Termination without Cause or Constructive Termination, then vesting for fifty percent (50%) of the then unvested First Milestone Shares shall accelerate as of such Termination without Cause or Constructive Termination (such that the Repurchase Right shall automatically terminate as to such First Milestone Shares); and (ii) if the Second Milestone shall have occurred prior to such Termination without Cause or Constructive Termination, then vesting for fifty percent (50%) of the then unvested Second Milestone Shares shall accelerate as of such Termination without Cause or Constructive Termination (such that the Repurchase Right shall automatically terminate as to such Second Milestone Shares).

 

(2)                                 Corporate Transaction.  In the event of any Corporate Transaction (so long as the Stockholder continues to be a Service Provider to the Company immediately prior to such Corporate Transaction), the following shall occur:  (i) vesting for fifty percent (50%) of the then unvested Time-Based Shares shall accelerate as of immediately prior to such Corporate Transaction (such that the Repurchase Right shall automatically terminate as to such Time-Based Shares) and the remaining Time-Based Shares shall vest, so long as the Stockholder continues to be a Service Provider to the Company, in equal monthly portions over the remainder of the original vesting schedule; (ii) if the First Milestone shall have occurred prior to the Corporate Transaction or if the Corporate Transaction results in at least the Threshold Return, then vesting for seventy-five percent (75%) of the then unvested First Milestone Shares shall accelerate as of immediately prior to such Corporate Transaction (such that the Repurchase Right shall automatically terminate as to such First Milestone Shares) and the remaining First Milestone Shares shall vest, so long as the Stockholder continues to be a Service Provider to the Company, in equal monthly portions over a remainder period that is the lesser of (x) six (6) months or (y) the time otherwise remaining on the original vesting schedule; and (iii) if the Second Milestone shall have occurred prior to the Corporate Transaction or if the Corporate Transaction results in at least the Threshold Return, then vesting for seventy-five percent (75%) of the then unvested Second Milestone Shares shall accelerate as of immediately prior to such Corporate Transaction (such that the Repurchase Right shall automatically terminate as to such Second Milestone Shares) and the remaining Second Milestone Shares shall vest, so long as the Stockholder continues to be a Service Provider to the Company, in equal monthly portions over a remainder period that is the lesser of (x) six (6) months or (y) the time otherwise remaining on the original vesting schedule.

 

(3)                                 Termination Without Cause or Constructive Termination following a Corporate Transaction.  In the event of any Termination without Cause or any Constructive Termination following any Corporate Transaction, the following shall occur: (i) if the First Milestone shall have occurred prior to such Termination without Cause or Constructive Termination or if the Corporate Transaction results in at least the Threshold Return, then vesting for all (100%) of the then unvested First Milestone Shares shall accelerate as of such Termination without Cause or Constructive Termination (such that the Repurchase Right shall

 

8

 

automatically terminate as to such First Milestone Shares); (ii) if the Second Milestone shall have occurred prior to such Termination without Cause or Constructive Termination or if the Corporate Transaction results in at least the Threshold Return, then vesting for all (100%) of the then unvested Second Milestone Shares shall accelerate as of such Termination without Cause or Constructive Termination (such that the Repurchase Right shall automatically terminate as to such Second Milestone Shares); and (iii) vesting for all (100%) of the then unvested Time-Based Shares shall accelerate as of such Termination without Cause or Constructive Termination (such that the Repurchase Right shall automatically terminate as to such Time-Based Shares).

 

(b)                                 Definitions.  For purposes of this Section 5.6:

 

(1)                                 A “Corporate Transaction” is defined as any of the following: (x) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) unless, following the consummation thereof, the Company’s stockholders of record immediately prior thereto hold more than fifty percent (50%) of the voting power of the surviving or acquiring entity or any direct or indirect parent entity of any such entity (with reference to the provisions of Section 8.2 below for determining such status); (y) the sale, transfer or other disposition of all or substantially all of the assets of the Company by means of any transaction or series of related transactions unless, following the consummation thereof, the Company’s stockholders of record immediately prior thereto hold more than fifty percent (50%) of the voting power of the acquiring entity or any direct or indirect parent entity of any such entity (with reference to the provisions of Section 8.2 below for determining such status); or (z) a sale of all or substantially all of the capital stock of the Company unless, following the consummation thereof, the Company’s stockholders of record immediately prior thereto hold more than fifty percent (50%) of the voting power of the acquiring entity or any direct or indirect parent entity of any such entity (with reference to the provisions of Section 8.2 below for determining such status); provided, however, that notwithstanding the foregoing, a Corporate Transaction shall not include (i) any sale of securities by the Company the primary purpose of which is to generate financing for the Company or (ii) any transaction effected exclusively for the purpose of changing the domicile of the Company.

 

(2)                                 A “Termination without Cause” means the termination, by the Company or one or more of its parent or subsidiary corporations, of any employment or consulting relationship between the Stockholder and the Company or one or more of its parent or subsidiary corporations for any reason other than: (i) commission by the Stockholder of any act of fraud or embezzlement; (ii) any intentional, unauthorized use or disclosure of material confidential information or trade secrets of the Company or one or more of its parent or subsidiary corporations by the Stockholder; or (iii) any other intentional misconduct by the Stockholder (including severe absenteeism) which adversely affects the business or affairs of the Company or one or more of its parent or subsidiary corporations in a material manner.

 

(3)                                 A “Constructive Termination” means the Stockholder’s election in a written notice to the Company or one or more of its parent or subsidiary corporations to terminate any employment or consulting relationship where such notice is delivered within thirty (30) days after any of the following: (i) a material reduction in the Stockholder’s level of duties or responsibilities or the nature of the Stockholder’s functions; (ii) a

 

9

 

material reduction in the Stockholder’s base salary or potential total cash compensation (consisting of base salary and target bonus); or (iii) a relocation of the Stockholder’s principal place of employment by more than fifty (50) miles, if the new location is both (A) more than fifty (50) miles from the Stockholder’s principal residence and (B) farther from the Stockholder’s principal residence than the Stockholder’s principal place of employment immediately before such relocation.

 

(4)                                 The “Threshold Return” means that: (i) within three (3) years after the Vesting Measurement Date, the investors in the Company’s shares of preferred stock actually receive, from a Corporate Transaction, an aggregate amount of distributions, payments or other consideration in respect of their shares of Company preferred stock which is equal to three (3) times the amount of their collective investment in such shares of Company preferred stock; (ii) after three (3) but within five (5) years after the Vesting Measurement Date, the investors in the Company’s shares of preferred stock actually receive, from a Corporate Transaction, an aggregate amount of distributions, payments or other consideration in respect of their shares of Company preferred stock which is equal to five (5) times the amount of their collective investment in such shares of Company preferred stock; or (iii) beyond five (5) years after the Vesting Measurement Date, the investors in the Company’s shares of preferred stock actually receive, from a Corporate Transaction, an aggregate amount of distributions, payments or other consideration in respect of their shares of Company preferred stock which is determined to be sufficient by the Company’s Board of Directors in its sole discretion to constitute the Threshold Return for purposes of this Agreement (but which is greater, in any event, than five (5) times the amount of their collective investment in such shares of Company preferred stock).  Determinations with respect to the value of any payments, distributions or other consideration (where other than in cash or marketable securities) shall be made in good faith by the Company’s Board of Directors.

 

5.7                               Legend.  In addition to the legends required by Section 2.4 above and Article 7 below, all certificates representing Shares subject to the Company’s Right of Repurchase shall be endorsed with the following legend:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF A WRITTEN AGREEMENT BETWEEN THE COMPANY AND THE INITIAL HOLDER HEREOF.  SUCH AGREEMENT PROVIDES FOR CERTAIN RESTRICTIONS ON TRANSFER OF THE SECURITIES, INCLUDING CERTAIN REPURCHASE RIGHTS IN FAVOR OF THE COMPANY UPON TERMINATION OF SERVICE WITH THE COMPANY.  THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.”

 

10

 

6.                                      Escrow.

 

6.1                               Deposit.  Upon issuance, the certificates for the Shares shall be deposited in escrow with the Secretary of the Company to be held in accordance with the provisions of this Article 6.  Each deposited certificate shall be accompanied by a duly executed Assignment  Separate from Certificate in the form of Exhibit A, attached hereto.  The deposited certificates, together with any other assets or securities from time to time deposited with the Company pursuant to the requirements of this Agreement, shall remain in escrow until such time or times as the certificates (or other assets and securities) are to be released or otherwise surrendered for cancellation in accordance with Section 6.3 below.  Upon delivery of the certificates (or other assets and securities) to the Company, the Owner shall be issued an instrument of deposit acknowledging the number of Shares (or other assets and securities) delivered in escrow to the Secretary of the Company.

 

6.2                               Recapitalization.  All regular cash dividends on the Shares (or other securities at the time held in escrow) shall be paid directly to the Owner and shall not be held in escrow.  However, in the event of any stock dividend, stock split, recapitalization or other change affecting the Company’s outstanding Common Stock as a class effected without receipt of consideration or in the event of any corporate reorganization, any new, substituted or additional securities or other property which is by reason of such transaction distributed with respect to the Shares shall be immediately delivered to the Secretary of the Company to be held in escrow under this Article 6, but only to the extent the Shares are at the time subject to the escrow requirements of Section 6.1 above.

 

6.3                               Release/Surrender.  The Shares, together with any other assets or securities held in escrow hereunder, shall be subject to the following terms and conditions relating to their release from escrow or their surrender to the Company for repurchase and cancellation:

 

(a)                                 Should the Company exercise the Repurchase Right under Article 5 above with respect to any Unvested Shares, then the escrowed certificates for such Unvested Shares (together with any other assets or securities issued with respect thereto) shall be delivered to the Company for cancellation, concurrently with the payment to the Owner, in cash or cash equivalent (including the cancellation of any purchase-money indebtedness), of an amount equal to the aggregate Repurchase Price for such Unvested Shares, and the Owner shall have no further rights with respect to such Unvested Shares (or other assets or securities).

 

(b)                                 As the interest of Stockholder in the Shares (or any other assets or securities issued with respect thereto) vests in accordance with the provisions of Article 5 above, the certificates for such vested shares (as well as all other vested assets and securities) shall be released from escrow and delivered to the Owner, if requested by the Owner, in accordance with the following schedule:

 

(1)                                 Releases of vested shares (or other vested assets and securities) from escrow shall be effected at annual intervals, with the first such annual release to occur twelve (12) months after the Vesting Measurement Date;

 

(2)                                 Upon Stockholder’s cessation of Service Provider status, any escrowed Shares (or other assets or securities) in which Stockholder is at the time vested shall be promptly released from escrow; and

 

11

 

(3)                                 Upon any earlier termination of the Repurchase Right in accordance with the applicable provisions of Article 5 above, the Shares (or other assets or securities) at the time held in escrow hereunder shall promptly be released to the Owner as fully vested shares or other property.

 

(c)                                  All Shares (or other assets or securities) released from escrow in accordance with the provisions of subsection (b) above shall nevertheless remain subject to the market stand-off provisions of Section 3.3 above and the Company’s Right of First Refusal until such provisions terminate in accordance herewith.

 

7.                                      Right of First Refusal.  Before any Shares may be sold or transferred (assuming compliance with the other provisions of this Agreement), other than pursuant to an Exempt Transfer, the Company shall have a right to repurchase such Shares (the “Right of First Refusal”) as follows:

 

7.1                               Transfer Notice.  The Owner (or any successor in interest) must give written notice (“Transfer Notice”) to the Company describing fully the proposed transfer, including the proposed transfer price and the name and address of the proposed transferee.  The Transfer Notice shall be signed both by the Owner and the proposed transferee and must constitute a binding commitment of both parties to the transfer of the Common Stock (subject to the exercise by the Company of its Right of First Refusal).

 

7.2                               Company’s Right to Repurchase.  The Company and its assignees shall have the right to purchase the Shares on the terms described in the Transfer Notice (subject, however, to any change in such terms permitted in Section 7.3 below) by delivery of a written notice within thirty (30) days after the date when the Transfer Notice was received by the Company; provided, however, in the event a transfer is proposed to be made without consideration (e.g., in the instance of a transfer resulting from the Owner’s will or the laws of intestate succession), the Company shall have the right to purchase the Shares at the then current fair market value of the Shares as determined in good faith by the Company’s Board of Directors.

 

7.3                               Owner’s Right to Transfer.  If the Company fails to exercise the Right of First Refusal within thirty (30) days after the date when it received the Transfer Notice, the Owner may conclude the proposed transfer not later than three (3) months following the Company’s receipt of the Transfer Notice, but only on the terms and conditions described in the Transfer Notice.  Any proposed transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed transfer by the holder, shall again be subject to the Right of First Refusal and shall require compliance with the procedure described in this Article 7.  If the Company exercises its Right of First Refusal, the Owner of the Shares and the Company (or its assignees) shall consummate the sale of the Shares on the terms set forth in the Transfer Notice; provided, however, in the event a transfer is proposed to be made without consideration (e.g., in the instance of a transfer resulting from the Owner’s will or the laws of intestate succession), the Company shall have the right to purchase the Shares at the then current fair market value of the Shares as determined in good faith by the Company’s Board of Directors.

 

12

 

7.4                               Successors and Assigns.  The Right of First Refusal shall inure to the benefit of the Company’s successors and assigns and shall be binding upon any transferee of the Shares.  Without limiting the foregoing, the Company’s rights under this Article 7 shall be freely assignable, in whole or in part.

 

7.5                               Listing Date Termination.  The Right of First Refusal pursuant to this Article 7 shall terminate on the Listing Date.  “Listing Date” means the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system if such securities exchange or interdealer quotation system has been certified in accordance with the provisions of Section 25100(o) of the California Corporate Securities Law of 1968.

 

7.6                               Legend.  In addition to the legends required by Section 2.4 and Section 5.7 above, all certificates representing Shares subject to the Company’s Right of First Refusal shall be endorsed with the following legend:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF A WRITTEN AGREEMENT BETWEEN THE COMPANY AND THE INITIAL HOLDER HEREOF.  SUCH AGREEMENT PROVIDES FOR CERTAIN RESTRICTIONS ON TRANSFER OF THE SECURITIES, INCLUDING CERTAIN RIGHTS OF FIRST REFUSAL IN FAVOR OF THE COMPANY.  THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.”

 

8.                                      General Provisions.

 

8.1                               Assignment.  The Company may assign its Repurchase Rights under Article 5 above to any person or entity selected by the Company’s Board of Directors, including one or more stockholders of the Company.

 

8.2                               Definitions.  For purposes of this Agreement, the following provisions shall be applicable in determining the parent and subsidiary corporations of the Company:

 

(a)                                 Any corporation (other than the Company) in an unbroken chain of corporations ending with the Company shall be considered to be a parent corporation of the Company, provided each such corporation in the unbroken chain (other than the Company) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

 

(b)                                 Each corporation (other than the Company) in an unbroken chain of corporations beginning with the Company shall be considered to be a subsidiary of the Company, provided each such corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

 

13

 

8.3                               No Employment or Service Contract.  Nothing in this Agreement shall confer upon Stockholder any right to continue in the service of the Company (or any parent or subsidiary corporation of the Company) for any period of time or restrict in any way the rights of the Company (or any parent or subsidiary corporation of the Company) or the Stockholder to terminate the Service Provider status of the Stockholder at any time for any reason whatsoever, with or without cause.

 

8.4                               Notices.  Any notice required in connection with (i) the Repurchase Right or (ii) the disposition of any Shares covered thereby shall be given in writing and shall be deemed effective upon personal delivery, upon deposit with a nationally recognized courier service, or upon deposit in the United States mail, registered or certified, postage prepaid and addressed to the party entitled to such notice at the address indicated below such party’s signature line on this Agreement or at such other address as such party may designate by ten (10) days advance written notice under this Section 8.4 to all other parties to this Agreement.

 

8.5                               No Waiver.  The failure of the Company (or its assignees) in any instance to exercise the Repurchase Right granted under Article 5 above or the Company’s Right of First Refusal granted under Article 7 above shall not constitute a waiver of any other repurchase rights or rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Company and the Stockholder.  No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

 

8.6                               Cancellation of Shares.  If the Company (or its assignees) shall make available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased in accordance with the provisions of this Agreement, then from and after such time, the person from whom such Shares are to be repurchased shall no longer have any rights as a holder of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement), and such Shares shall be deemed purchased in accordance with the applicable provisions hereof and the Company (or its assignees) shall be deemed the owner and holder of such Shares, whether or not the certificates therefor have been delivered as required by this Agreement.

 

8.7                               Stockholder Undertaking.  The Stockholder hereby agrees to take whatever additional action and execute whatever additional documents the Company may in its judgment deem necessary or advisable in order to carry out the obligations or restrictions imposed on the Stockholder under this Agreement.

 

8.8                               Agreement Is Entire Contract.  This Agreement constitutes the entire contract between the parties hereto with regard to the subject matter hereof.

 

8.9                               Governing Law.  This Agreement shall be governed by, and construed in accordance with, the laws of the State of California, as such laws are applied to contracts entered into and performed in such State.

 

14

 

8.10                        Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

 

8.11                        Successors and Assigns.  The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and the Stockholder and the Stockholder’s legal representatives, heirs, legatees, distributees, assigns and transferees by operation of law, whether or not any such person shall have become a party to this Agreement and have agreed in writing to join herein and be bound by the terms and conditions hereof.

 

IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first indicated above.

 

	
 
    	
RECEPTOS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ William H. Rastetter
    
	
 
    	
Name:
    	
William   H. Rastetter
    
	
 
    	
Its:
    	
CEO
    
	
 
    	
 
    	
 
    
	
STOCKHOLDER:*
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Marcus Boehm
    	
 
    	
 
    
	
Marcus Boehm
    	
 
    	
 
    
				

 

*                                         I have received and retained the Code Section 83(b) election that was attached hereto as Exhibit B.  As set forth in Section 3.2, I understand that I, and not the Company, will be responsible for completing the form and filing the election with the U.S. Internal Revenue Service and that if such filing is not completed within thirty (30) days after the date of this Agreement, I will forfeit the potentially significant tax benefits of Section 83(b) of the Code.  I understand further that such filing should be made by registered or certified mail, return receipt requested, and that I must retain two (2) copies of the completed form for filing with my state and federal tax returns for the current tax year and an additional copy for my records.

 

15

 

Spousal Consent

 

Rosemary A. Straney (Stockholder’s spouse) indicates by the execution of this Agreement such spouse’s consent to be bound by the terms herein as to such spouse’s interests, whether as community property or otherwise, if any, in the Shares.

 

 

	
 
    	
/s/ Rosemary A. Straney
    
	
 
    	
(Signature)
    
	
 
    	
 
    
	
 
    	
Rosemary A. Straney
    
	
 
    	
(Printed Name)
    

 

16

 

EXHIBIT A

 

Assignment Separate From Certificate

 

FOR VALUE RECEIVED                                      (“Stockholder”) hereby sells, assigns and transfers unto RECEPTOS, INC., a Delaware corporation (the “Company”),                          (                ) shares of Common Stock of the Company represented by Certificate No.            herewith and does hereby irrevocably constitute and appoint                                                      Attorney to transfer the said stock on the books of the Company with full power of substitution in the premises.

 

	
Dated:                           ,   20    .
    
	
 
    
	
 
    
	
 
    	
/s/ Marcus Boehm
    
	
 
    	
(Signature)
    

 

Spousal Consent

 

(Stockholder’s spouse) indicates by the execution of this Assignment such spouse’s consent to be bound by the terms herein as to such spouse’s interests, whether as community property or otherwise, if any, in the Shares.

 

	
 
    	
/s/ Rosemary A. Straney
    
	
 
    	
(Signature)
    
	
 
    	
 
    
	
 
    	
Rosemary A. Straney
    
	
 
    	
(Printed Name)
    

 

INSTRUCTIONS:  PLEASE DO NOT FILL IN ANY BLANKS OTHER THAN THE SIGNATURE LINE.  THE PURPOSE OF THIS ASSIGNMENT IS TO ENABLE THE COMPANY TO EXERCISE ITS “REPURCHASE OPTION” SET FORTH IN THE AGREEMENT WITHOUT REQUIRING ADDITIONAL SIGNATURES ON THE PART OF STOCKHOLDER.

 

 

EXHIBIT B

 

ELECTION UNDER SECTION 83(b) OF

THE INTERNAL REVENUE CODE

 

The undersigned hereby makes an election pursuant to Section 83(b) of the Internal Revenue Code with respect to the property described below and supplies the following information in accordance with the regulations promulgated thereunder:

 

(A)                               The name, address and social security number of the undersigned:

 

Marcus Boehm

 

 

Social Security No.:

 

(B)                               Description of property with respect to which the election is being made:

 

800,000 shares of Common Stock of Receptos, Inc. (the “Company”).

 

(C)                               The date on which the property was transferred is July       , 2009.

 

(D)                               The taxable year to which this election relates is calendar year 2009.

 

(E)                                Nature of restrictions to which the property is subject:  The shares of stock transferred to the undersigned taxpayer are subject to the provisions of a Restricted Stock Issuance Agreement between the undersigned and the Company.  Under the provisions of the Agreement, the Company will have the right to repurchase the stock at a price which may be less than the fair market value of the shares in the event of the undersigned’s termination of employment with the Company.  This right will lapse over a four-year period, although a portion of the shares are subject to a repurchase right that may take longer to lapse.

 

(F)                                 The fair market value of the property at the time of transfer (determined without regard to any restriction other than any restriction which by its terms will never lapse) was $0.01 per share, for a total of $8,000.

 

(G)                               The amount paid by taxpayer for the property was $0.

 

(H)                              A copy of this statement has been furnished to the Company.

 

	
Dated:                          , 2009
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
(Signature)Exhibit 10.37

 

AMENDED AND RESTATED CONSULTING AGREEMENT

 

This is to confirm the agreement between Edward Roberts (“Consultant”), and Receptos, Inc., a Delaware corporation (the “Company”), for consulting services (the “Agreement”).

 

Whereas, Consultant and the Company are parties to that certain Consulting Agreement, deemed to have commenced May 11, 2009 (the “Original Consulting Agreement”) pertaining to consulting services provided by Consultant to the Company; and

 

Whereas the Company and Consultant now desire to amend the Original Consulting Agreement.

 

Therefore Consultant and the Company agree as follows:

 

1.                                      Amendment and Restatement.  The Original Consulting Agreement is hereby amended and restated in its entirety by this Agreement effective as of January 1, 2013.

 

2.                                      Term of Agreement.  The term of this Agreement is deemed to have commenced on May 11, 2009, and will continue in effect until terminated as provided herein.

 

3.                                      Services To Be Performed by Consultant.  Consultant agrees to provide consulting services to the Company with respect to its research and development activities.  The amount of time Consultant is expected to spend on these activities for Company is set forth on Exhibit A attached hereto.

 

4.                                      The Scripps Research Institute.  The Company understands that Consultant is an employee of The Scripps Research Institute (the “Institute”).  All services provided by Consultant to Company shall be made in accordance with the Institute’s Uniform Consulting Agreement Provisions (the “Uniform Provisions”), appended hereto as Exhibit B and incorporated by specific reference.  This Agreement shall be subject to the Uniform Provisions and if anything in this Agreement is inconsistent with the Uniform Provisions, the Uniform Provisions shall govern.  Consultant represents that this Agreement and Consultant’s duties hereunder do not conflict with the Uniform Provisions, and Consultant further represents and warrants that Consultant has the full right to enter into this Agreement, and Consultant has the right to perform his duties hereunder, without breaching or violating any fiduciary, contractual, or statutory obligations owed to another.

 

5.                                      Acknowledgement. The Company recognizes that in connection with Consultant’s employment by the Institute, Consultant:  (a) has certain responsibilities with respect to intellectual property matters to the Institute; and (b) must abide by the Uniform Provisions.  The Company hereby acknowledges the existence of the Uniform Provisions and agrees to take no actions which would result in Consultant violating the Uniform Provisions.  Notwithstanding the foregoing, Consultant hereby represents, warrants and covenants that: (i) Consultant’s activities for the Company are, relative to the Institute, entirely on Consultant’s own time; (ii) Consultant will not violate any of the terms and conditions of the Uniform Provisions; (iii) Consultant’s activities for the Company are separate and apart from any services that may be provided to the Company indirectly through Consultant’s performance, on behalf of the Institute, of any activities in respect of a Company-funded research agreement between the Company and the

 

 

Institute (“Funded Research”); (iv) in performing Consultant’s activities for the Company, except for nominal use of Institute’s office, telephone and computer as expressly permitted pursuant to the Uniform Provisions, Consultant will not use the facilities, equipment, supplies, funding, inventions, trade secrets or other resources or proprietary rights of the Institute; and (v) except to the extent of any Funded Research, or where the Company has already licensed the results of such research, Consultant’s activities for the Company will not, to the best of Consultant’s knowledge, (A) relate to the Institute’s business or actual or demonstrably anticipated research or development activities or (B) result from or relate to any work performed for the Institute.

 

6.                                      Compensation.  The Company will compensate Consultant for Consultant’s performance of this Agreement as set forth on Exhibit A attached hereto.

 

7.                                      Exclusivity.  Consultant agrees that Consultant will not, without the prior written consent of the Company (which may be withheld in its sole discretion), enter into any agreement to perform (or otherwise perform) services for any entity, other than Company or the Institute, engaged in any activities that are within the field of any modulators of the S1P family (including but not limited to S1P1, S1P2, S1P3, S1P4, and S1P5 receptors).

 

8.                                      Confidential Information.

 

(a)                                 Consultant acknowledges that the Company possesses and will continue to possess information that has been created, discovered or developed by or on behalf of, or has otherwise become known to, the Company, including, without limitation, information (i) created, discovered, or developed by Consultant or made known to Company by Consultant (and within the scope of this Agreement) or to Consultant arising out of Consultant’s retention as a consultant by the Company, and/or (ii) in which property rights have been assigned or otherwise conveyed to the Company, which information has commercial value in the business in which the Company is engaged.  All of the aforementioned information is hereinafter called “Confidential Information.”  By way of illustration, but not limitation, Confidential Information includes all data, compilations, specifications, strategies, projections, processes, techniques, formulae, models and patent disclosures; and all tangible and intangible embodiments thereof of any kind whatsoever including, where appropriate and without limitation, all compositions, machinery, apparatus, records, reports, drawings, patent applications and documents.

 

(b)                                 Subject, to the extent applicable, to the Uniform Provisions, Consultant agrees that: (a) all Confidential Information shall be the sole property of the Company and its assigns, and Company and its assigns shall be the sole owner of all patents and other rights in connection therewith; (b) Consultant hereby assigns to the Company any rights Consultant may have or acquire in all Confidential Information; and (c) at all times during the term of this Agreement, as well as at all times after any termination, Consultant will keep in confidence and trust all Confidential Information, and Consultant will not use or disclose any Confidential Information or anything relating to it without the written consent of the Company, except as may be necessary in the ordinary course of performing Consultant’s duties as a consultant to the Company as contemplated hereby; provided, however, that such obligations of confidentiality shall not apply to such information as Consultant can establish by written documentation to:  (i) have been publicly known prior to disclosure by the Company of such information to Consultant;

 

2

 

(ii) have become publicly known, without fault on Consultant’s part, subsequent to disclosure by the Company of such information to Consultant; (iii) have been received by Consultant at any time from a source, other than the Company, lawfully having (x) possession of and the right to disclose such information to Consultant and (y) the right to permit Consultant to disclose publicly such information; or (iv) have been otherwise known by Consultant (and without an obligation to keep the same in confidence for the benefit of the Company) prior to disclosure by the Company to Consultant of such information.  Notwithstanding the foregoing, Consultant shall have the right to disclose Confidential Information to the extent required by applicable law or regulation, provided that Consultant gives the Company prompt written notice and sufficient opportunity to object to such use or disclosure, or to request confidential treatment of the Confidential Information.

 

(c)                                  All documents, data, records, apparatus, equipment and other physical property, whether or not pertaining to Confidential Information, furnished to Consultant by the Company or, to the extent permitted by the Uniform Provisions, produced by Consultant or others in connection with Consultant’s performance of activities for the Company shall be and remain the sole property of the Company and shall be returned promptly to the Company as and when requested by the Company.  Should the Company not so request, Consultant shall return and deliver all such property upon any termination of the Agreement and Consultant will not take with Consultant any such property or any reproduction of such property upon such termination.

 

9.                                      Inventions.  Subject, to the extent applicable, to the Uniform Provisions:

 

(a)                                 Consultant will promptly disclose to the Company, or any persons designated by it, all improvements, inventions, formulae, processes, techniques, know-how and data, whether or not patentable, made or conceived or reduced to practice or learned by Consultant, either alone or jointly with others, during the period of Consultant’s retention to provide services to the Company hereunder which (i) are so made, conceived, reduced to practice, or learned in the course of providing services under this Agreement and related to or useful in the business of the Company, (ii) result from tasks assigned Consultant by the Company under this Agreement, (iii) are funded by the Company and such funding gives Company the right of ownership, or (iv) result from use of premises owned, leased or contracted for by the Company (all said improvements, inventions, formulae, processes, techniques, know-how and data shall be collectively hereinafter called “Inventions”).  Such disclosure shall continue for one year after termination of this Agreement with respect to anything that would be an Invention if made, conceived, reduced to practice or learned during the term hereof.

 

(b)                                 Consultant (i) agrees that all Inventions (except for such Inventions the ownership of which is provided under a Funded Research agreement) shall be the sole property of the Company and its assigns, and the Company and its assigns shall be the sole owner of all patents and other rights in connection therewith; (ii) hereby assigns to the Company all right, title and interest Consultant may have or acquire in all such Inventions; and (iii) further agrees as to all Inventions to assist the Company in every proper way (but at the Company’s expense) to obtain and from time to time enforce patents on the Inventions in any and all countries, and to that end Consultant will execute all documents for use in applying for and obtaining such patents thereon and enforcing same, as the Company may desire, together with any assignments thereof to the Company or persons designated by it.  Consultant’s obligation to assist the Company in

 

3

 

obtaining and enforcing patents for the Inventions in any and all countries shall continue beyond the termination of this Agreement, but the Company shall compensate the Consultant at a reasonable rate commensurate with rates paid by others for comparable services after such termination for time actually spent by Consultant at the Company’s request on such assistance.  In the event that the Company is unable for any reason whatsoever to secure Consultant’s signature to any lawful and necessary document required to apply for or execute any patent application with respect to Inventions (including renewals, extensions, continuations, divisions or continuations in part thereof), Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents, as Consultant’s agents and attorneys-in-fact to act for and in Consultant’s behalf and instead of Consultant, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents thereon with the same legal force and effect as if executed by Consultant.

 

10.                               No Conflict.  Consultant represents, warrants and covenants that:

 

(a)                                 Consultant’s performance of the terms of this Agreement and Consultant’s retention as a consultant to the Company as contemplated hereby does not and will not breach any agreement to keep in confidence proprietary information acquired by Consultant in confidence or in trust prior to or following the date hereof;

 

(b)                                 Consultant has not entered into, and will not enter into, any agreement (either written or oral) in conflict with this Agreement;

 

(c)                                  Except as permitted by the Institute in the course of Consultant’s performance of Consultant’s duties in connection with a Funded Research agreement, Consultant has not brought, and will not bring, with Consultant to the Company, or use in the performance of any activities for the Company, any equipment, facilities, supplies, inventions, trade secrets or other resources or proprietary rights of any employer (current or former) or other third party;

 

(d)                                 Consultant will not breach any obligation of confidentiality to Company or others; and

 

(e)                                  Consultant will not, during the term of this Agreement and for a period of one year following any termination, solicit or in any manner encourage employees or consultants of the Company to leave its employ.

 

11.                               Independent Consultant Relationship.  Consultant and the Company agree that no employment relationship is created between Consultant and Company by this Agreement.  The Company is interested only in the results to be achieved by Consultant.  Consultant is an independent contractor and is not considered an agent or common law employee of the Company for any purpose.  Consultant shall be solely responsible for and shall make proper and timely payment of any taxes due on payments made or any other consideration provided (a) to Consultant pursuant to this Agreement (including, but not limited to, Consultant’s estimated state and federal income taxes and self-employment taxes) and (b) to any other persons (if applicable) who provide services to Consultant in connection with this Agreement.  Consultant hereby agrees to indemnify the Company against any and all claims, liabilities or expenses (including, without limitation, attorneys’ fees and costs) the Company incurs as a result of Consultant’s breach of any of Consultant’s obligations under this Section 11.

 

4

 

12.                               Termination.  This Agreement shall terminate automatically on the occurrence of any of the following events:

 

(a)                                 Death of Consultant;

 

(b)                                 Any attempted assignment of this Agreement by Consultant;

 

(c)                                  Thirty (30) days’ notice to Consultant by the Company;

 

(d)                                 Immediately upon written notice to Consultant by the Company of a Material Breach (as defined below) by Consultant; or

 

(e)                                  Thirty (30) days’ notice to the Company by Consultant, so long as no such notice is delivered by Consultant during the term of any Funded Research agreement.

 

For purposes of this Agreement, “Material Breach” shall include, but not be limited to, Consultant’s failure to provide consulting services to the Company in a timely fashion, Consultant’s habitual neglect, negligence or wrongdoing in the performance of Consultant’s duties, or Consultant’s breach of any provision hereof.

 

13.                               Modifications.  No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto.

 

14.                               Injunctive Relief.  Consultant agrees that in addition to any other rights and remedies available to the Company for any breach by Consultant of any obligation hereunder, the Company shall be entitled to enforcement of such obligation by court injunction.

 

15.                               Severability.  If any provision of this Agreement shall be declared invalid, illegal or unenforceable, such provision shall be severed and all remaining provisions shall continue in full force and effect.  This Agreement shall be effective as of the date hereof.  The term “Company” as used herein shall include any subsidiary or affiliate of the Company.  This Agreement shall be binding upon Consultant as well as Consultant’s heirs, executors, assigns and administrators and shall inure to the benefit of the Company and its successors and assigns.  This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to the conflicts of law principles thereof.

 

16.                               Acknowledgment.  Consultant certifies and acknowledges that Consultant has carefully read all of the provisions of this Agreement and Consultant understands and will fully and faithfully comply with such provisions.  Consultant agrees that this Agreement supersedes and cancels any and all previous agreements of whatever nature between the Company and Consultant with respect to the matters covered herein.  This Agreement constitutes the full, complete and exclusive agreement between Consultant and the Company with respect to the subject matters herein.

 

5

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above (i.e., the first date of the term of this Agreement).

 

	
 
    	
RECEPTOS, INC.,
    
	
 
    	
a Delaware corporation
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Faheem Hasnain
    
	
 
    	
Name:
    	
Faheem Hasnain
    
	
 
    	
Title:
    	
CEO
    
	
 
    	
 
    	
 
    
	
 
    	
CONSULTANT:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
/s/ Edwards Roberts
    
	
 
    	
Name:
    	
Edward Roberts
    

 

6

 

 

EXHIBIT A

 

Amount of Time/Nature of Services

 

	
Amount:
    	
Consultant shall provide, as and when reasonably   requested by the Company,  consulting services to the Company under the   Agreement in an amount up to eight hours per month.  The amount of   consulting services provided hereunder shall be exclusive of any duties as   Consultant may have to the Company on behalf of the Institute pursuant to any   Funded Research agreement.
    
	
 
    	
 
    
	
Compensation:
    	
Consultant shall be compensated for Consultant’s   performance of services hereunder as follows:

 

(i)                                     prior   to July 1, 2012, $2,000 per day of consulting services performed for and   at the request of the Company, and, commencing July 1, 2012, $3,000 per   month during the remainder of the term of the Agreement, payable quarterly and   in arrears; and

 

(ii)                                  the   vesting of an option held by Consultant to acquire up to two hundred fifty   thousand (250,000) shares of the Company’s Common Stock, which option shall   be subject to vesting and other provisions as set forth in the amendment dated   May 11, 2009 to the Stock Option Agreement, dated November 28,   2008,  between Company and Consultant.

 

In addition, Consultant shall be reimbursed for   reasonable expenses incurred by Consultant in the performance of consulting   obligations hereunder within thirty (30) days of invoice; provided, however,   that expenses shall be (i) invoiced on a monthly basis, (ii) consistent   with the policies of the Company therefor and (iii) incurred only with   the prior written consent of the Company.

 

Consultant acknowledges and agrees that the   foregoing compensation arrangements constitute the sole compensation that   Consultant may receive for the performance of Consultant’s obligations under   the Agreement (except as expressly contemplated therein with respect to   certain post-termination activities performed by Consultant and involving the   protection of Inventions on behalf of the Company), and any other claims or   Consultant, or obligations of the Company, with respect to any such   compensation are waived and released by Consultant.
    

 

 

EXHIBIT B

 

THE SCRIPPS RESEARCH INSTITUTE
 UNIFORM CONSULTING AGREEMENT PROVISIONS

 

For Different Technologies between Consultant’s TSRI Work and Consulting Services

 

1.                                      All arrangements and agreements in which any personnel of The Scripps Research Institute (“TSRI”) provides consulting services to any third party or entity (the “Company”) shall refer to these Uniform Consulting Agreement Provisions (“UCPs”) by attaching these UCPs to the consulting agreement.  These UCPs are hereby incorporated into the consulting agreement between the Company and the TSRI employee who will provide consulting services to the Company (“Consultant”).  Notwithstanding anything to the contrary in the consulting agreement between the Company and Consultant (“Consulting Agreement”), if any provision in the Consulting Agreement conflicts or is inconsistent with any of these UCPs, these UCPs shall govern and control.  The Consulting Agreement shall not be effective unless it is approved in writing by TSRI’s management.

 

2.                                      Consultant shall spend no more than an aggregate of ten percent (10%) of his/her total professional time and effort in providing consulting services to all outside third parties, including the Company.  Consulting fees shall be paid directly to the Consultant.

 

3.                                      TSRI’s name, trademarks, logos or reputation shall not be used or exploited directly or indirectly by the Company.  Neither Company nor Consultant shall use any services, personnel, facilities, equipment or intellectual property of TSRI in performing or accepting consulting services; provided, however, that Consultant’s nominal use of his TSRI laboratory office and telephone, and Consultant’s nominal use of the TSRI computer in his TSRI laboratory office for email communications (but not any other TSRI equipment, facilities or resources) for purposes of conducting his consulting services to the Company shall not be prohibited under these UCPs.  In addition, Consultant’s services to the Company shall not involve the design or conduct of any research or laboratory work and/or supervising Company’s employees or contractors in the designing or conducting of any research or laboratory work.  For clarity, Consultant’s review of literature applicable to the Company’s products or business or Consultant’s provision of general advice given as a member of the Company’s scientific advisory board or similar committee or general suggestions on future research work by the Company shall not constitute prohibited research activities under these UCPs.

 

4.                                      Consultant’s right, title and interest in and to inventions, discoveries, know-how, data, materials and other work conceived, reduced to practice, developed, generated or created by Consultant, alone or in collaboration with others, solely in the performance of his/her consulting services for the Company (collectively “Inventions”) may be assigned to the Company under the Consulting Agreement, provided that such Inventions (i) are developed entirely on Consultant’s own time and not while performing any work for or on behalf of TSRI, (ii) are developed without the use of any of TSRI’s equipment, supplies, facilities, personnel, funds or other monies under TSRI’s control, resources, data or confidential information, and (iii) do not constitute an invention conceived or reduced to practice in the performance of work under any of TSRI’s

 

8

 

grants or contracts with a federal governmental entity (i.e., a “Subject Invention” as defined in the Bayh-Dole Act [37 C.F.R. 401.14]) and/or do not constitute an invention or other discovery developed in the performance of work under any contract between TSRI and a third party using TSRI facilities, equipment or other resources and/or where the Consultant is performing any of the responsibilities or tasks under the scope of work or research project for the contract between TSRI and a third party.

 

5.                                      Company shall not obtain any right, title or interest in or to any invention, discovery, know-how, data, materials or other work of Consultant which was: (i) conceived, reduced to practice, developed, generated or created by Consultant before the effective date of the Consulting Agreement; or (ii) at any time conceived, reduced to practice, developed, generated or created outside the scope of or independent of his/her consulting services for the Company.

 

6.                                      The Company agrees that it shall not request Consultant to disclose to the Company or to any other party any confidential or proprietary information or materials of TSRI or of other third parties in TSRI’s possession or control.  Consultant further agrees not to disclose or otherwise disseminate to Company or any other party as part of the consulting services any of TSRI’s confidential or proprietary information or materials or that of third parties in TSRI’s possession or control.

 

7.                                      In the event a dispute arises about whether TSRI or Company has any rights in an Invention that the other party claims to own, the determination of inventorship, conception and/or reduction to practice shall be determined jointly by patent counsel for TSRI and patent counsel for Company, according to the United States patent laws.  In the event such patent counsel cannot mutually agree, then the determination shall be by a qualified, independent patent lawyer nominated by TSRI and approved by Company, which approval shall not be unreasonably withheld or delayed.  The independent patent attorney shall serve as a sole arbitrator, to whom TSRI and Company shall submit their evidence and arguments.  If Company does not approve the appointment of the independent patent lawyer selected by TSRI, then the San Diego County Superior Court shall appoint an independent patent lawyer with at least ten (10) years experience in arbitrating or mediating inventorship disputes to serve as the arbitrator.  TSRI and Company shall each pay fifty percent (50%) of the fees and costs of the independent patent attorney.  The arbitrator may interview any persons and review any documents which the arbitrator deems necessary or proper to reach a determination.  The arbitrator’s determination shall be binding upon TSRI and Company.

 

8.                                      Nothing in the Consulting Agreement shall limit or impair in any way the right of Consultant or TSRI to use or disclose information which (a) was or becomes part of the public domain without Consultant’s breach of any confidentiality obligations owed to the Company or TSRI; (b) was known by TSRI or Consultant before the effective date of the Consulting Agreement; (c) was developed or acquired independently of the Company or TSRI; (d) is covered under Section 5 above; (e) was received from a third party who does not have any apparent obligation to the Company to maintain the confidentiality of such information; and/or (f) is required to be disclosed by law, order or governmental regulation or directive.

 

9

 

9.                                      The Company shall indemnify, defend and hold harmless TSRI and its trustees, officers, employees, affiliates, representatives, successors and assigns from all claims, damages, liabilities, losses, judgments and other expenses, including without limitation reasonable attorney’s fees and costs, whether or not a lawsuit or other proceeding is filed (“Claims”), that arise out of or relate to the Consulting Agreement, any services performed by Consultant for the Company, and/or Company’s use, commercialization or exploitation of any Inventions or services performed by Consultant for the Company.  Company shall not enter into any settlement of such Claims that imposes any obligation on TSRI or that does not unconditionally release TSRI from all liability without TSRI’s prior written consent.  This indemnity shall be a direct payment obligation and not merely a reimbursement obligation of Company to TSRI.

 

10.                               Upon termination of the consulting services, Consultant shall, upon Company’s request, leave all notes and records of his/her consulting services with Company, but shall be entitled to retain one (1) copy thereof for archival purposes, subject to his/her confidentiality obligations to the Company.

 

11.                               The Consulting Agreement and these UCPs shall be construed and enforced according to United States patent laws and the laws of the State of California without application of its conflicts or choice of law rules.  Sections 1, 3, 4, 5, 6, 7, 8, 9, 10 and 11 of these UCPs shall survive the expiration or termination of the Consulting Agreement.  These UCPs cannot be modified except by a writing signed by TSRI, Consultant and Company.  These UCPs constitute the entire agreement between the Company and TSRI regarding the consulting services to be performed by Consultant for the Company, and supersede any prior understandings or agreements, written or oral, regarding TSRI’s and the Company’s agreement about such consulting services.

 

10

 

Company and Consultant hereby agree to the above UCPs

 

	
Company
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Faheem Hasnain
    	
 
    	
 
    
	
Title:
    	
CEO
    	
 
    
	
Date:
    	
01/24/13
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Consultant
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Edward Roberts
    	
 
    	
 
    
	
Date:
    	
12/31/12
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Acceptance: TSRI hereby   accepts the above UCP’s as part of the consulting agreement.
    
	
 
    	
 
    	
 
    
	
The   Scripps Research Institute
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Emily Holmes
    	
 
    	
 
    
	
Emily Holmes, Ph.D.
    	
 
    
	
Title: 
    	
Vice President, Research Services
    	
 
    
	
Date: 
    	
1-15-13
    	
 
    
					

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]